U-11634 是一种口服有效的多巴胺 β-羟化酶 (dopamine β-hydroxylase) 非竞争性抑制剂,对大鼠的 LD50 值为 1197 mg/kg (皮下注射) 和 524 mg/kg (口服),它可阻断多巴胺 (dopamine) 向去甲肾上腺素 (norepinephrine) 的转化并降低脑内去甲肾上腺素水平,通过膳食添加的方式降低食物摄入量与自主运动活性,可诱发甲状腺毒性并抑制妊娠,因此可用于妊娠的研究。
产品编号: MS-A56897 CAS No.: 3414-47-9 分子式: C11H10F3NO2S 分子量: 277.26
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

U-11634 是一种口服有效的多巴胺 β-羟化酶 (dopamine β-hydroxylase) 非竞争性抑制剂,对大鼠的 LD50 值为 1197 mg/kg (皮下注射) 和 524 mg/kg (口服),它可阻断多巴胺 (dopamine) 向去甲肾上腺素 (norepinephrine) 的转化并降低脑内去甲肾上腺素水平,通过膳食添加的方式降低食物摄入量与自主运动活性,可诱发甲状腺毒性并抑制妊娠,因此可用于妊娠的研究。

生物实验数据

生物活性 U-11634 is an orally active non-competitive inhibitor of dopamine β-hydroxylase with LD50 values of 1197 mg/kg (subcutaneous) and 524 mg/kg (oral) in rats; it blocks the conversion of dopamine to norepinephrine and reduces brain norepinephrine levels, decreases food intake and spontaneous locomotor activity via dietary administration, induces thyroid toxicity, and inhibits pregnancy, and thus can be used for research on pregnancy.
体外研究
(In Vitro)

U-11634 (compound 12) (1×10-4 M) 可在体外中度抑制纯化的牛肾上腺多巴胺 β-羟化酶,通过非竞争性抑制将酶活性降至对照组的 52%。

体内研究
(In Vivo)

U-11634 (compound 12) (200 mg/kg;腹腔注射;单剂量) 在单次 200 mg/kg 腹腔注射后 4 小时可将大鼠脑内去甲肾上腺素水平降至对照组的 82%,16 小时时降至对照组的 72%。
U-11634 (每 24 小时 616 mg/kg;口服;单次给药;持续 24 小时) 可将小鼠的自主活动能力降至对照组的 67%。
U-11634 (5-10 mg/天;每日皮下注射;连续 20 天) 不会改变处于发情周期的成年 Sprague-Dawley 雌性大鼠的阴道细胞学特征、体重增长、治疗后交配间隔或产仔结局。
U-11634 (每日 5-10 mg;皮下注射;每日 1 次;假妊娠第 4、5、6 天) 对 Sprague-Dawley 大鼠从假妊娠开始至首次给药后动情样涂片的间隔时间无显著改变。
U-11634 (25 mg;口服;单剂量) 经口服给予雌性 Sprague-Dawley 大鼠后,会被快速吸收,在 2 小时时达到 13.3 μg/mL 的血清峰值 (按 100 mg/kg 标准化),且血清药物浓度可稳定维持长达 24 小时。
U-11634 (200 mg/kg;口服;单次给药) 经口服给予雄性 cynomologous 猴后,表现出吸收缓慢的特征,两只动物在 12 小时时的血清峰值分别为 33.0 μg/mL 和 49.4 μg/mL,且在 24 小时内代谢/排泄缓慢。
U-11634 (0.25-10 mg;皮下注射;从发情前期至第 6 天每日给药;在第 2、4、6、12 或 16 天单次给药;从第 1 天至第 3 天每日给药;从第 3 天至第 6 天每日给药) 可在着床前早期阶段完全抑制 Sprague-Dawley 大鼠的妊娠,且治疗剂量下未观察到胚胎毒性。
U-11634 (3-12 mg/rat;膳食给药;从发情前期至第 6 天的平均每日摄入量) 可在着床前早期阶段完全抑制 Sprague-Dawley 大鼠的妊娠,且治疗剂量下未观察到胚胎毒性。
U-11634 (1.0-5.0 mg/rat;口服;从发情前期开始每日给药 7 天或 13 天) 可在着床前早期阶段完全抑制 Sprague-Dawley 大鼠的妊娠,且治疗剂量下未观察到胚胎毒性。
U-11634 (1.0-5.0 mg;皮下注射;第 1 天至第 8 天每日给药) 可抑制小鼠的妊娠。
U-11634 (0.25 mg/只小鼠;口服;第 1 天至第 8 天每日给药) 可显著抑制小鼠的妊娠。
U-11634 (每只大鼠 0.05-6.4 mg;皮下注射;每日 1 次,连续 10 天) 在抗生育剂量下对未成年雄性 Sprague-Dawley 大鼠无促性腺激素抑制活性,仅在治疗剂量 4 倍时观察到对生殖组织的轻微作用。
U-11634 (0.05-2.0 mg;口服;每日给药,连续 10 天) 在每日口服剂量高达 2.0 mg/rat 时,未在双侧卵巢切除的未成年 Sprague-Dawley 大鼠中表现出子宫增重活性或抗雌激素活性。
U-11634 (每只大鼠 0.5-8.0 mg;口服;连续给药 10 天) 在去势雄性幼年 Sprague-Dawley 大鼠中,即使每日口服剂量高达 8.0 mg/rat,也未表现出雄激素活性。
U-11634 (10 mg/只大鼠;口服;第 5 天至第 8 天每日给药) 可抑制完整以及经激素处理的去卵巢假孕 Sprague-Dawley 大鼠的蜕膜形成,支持干扰子宫内膜蜕膜化是其抑制妊娠的作用机制。
U-11634 (12.5-50 mg/kg;口服;妊娠第 9 天至第 15 天每日给药) 在妊娠中期每日口服剂量高达 50 mg/kg 时,不会对妊娠 Sprague-Dawley 大鼠造成显著的胎仔毒性、死亡或发育异常。

Animal Model: Sprague-Dawley (male, 140-200 g)
Dosage: 200 mg/kg
Administration: i.p.; single dose
Result: Remained at 100% of control values at 2 hours post-dose.
Reduced to 82% of control values at 4 hours post-dose.
Reduced to 72% of control values at 16 hours post-dose.
Animal Model: CF-1 (male)
Dosage: 616 mg/kg
Administration: p.o.; single application for 24 h
Result: Reduced spontaneous motor activity to 67% of control values.
Animal Model: Sprague-Dawley (mature female, cyclic)
Dosage: 5 mg/day; 10 mg/day
Administration: s.c.; daily; 20 days
Result: Showed no effect on vaginal cytology relative to vehicle controls.
Did not significantly differ from controls in body-weight gain (5 mg/day group: +25 g; 10 mg/day group: +23 g), days from end of treatment to mating (5 mg/day group: 2.0 days; 10 mg/day group: 3.6 days), litter size (5 mg/day group: 11.6 foetuses; 10 mg/day group: 11.2 foetuses), average foetal weight (5 mg/day group: 2.9 g; 10 mg/day group: 2.6 g), and foetal gross condition.
Animal Model: Sprague-Dawley (lactating, litters reduced to 8 pups)
Dosage: 10 mg/day
Administration: s.c.; once daily; days 5, 6, 7 of lactation
Result: Showed no effect on pup weight (pups gained an average of 1.5 g body weight daily) or pup survival (no pup deaths) relative to controls.
Showed no effect on vaginal cytology timing (cornified oestrous smears observed on day 18 or 19, matching control timing) relative to controls.
Animal Model: Sprague-Dawley (female, 219-231 g)
Dosage: 100 mg/kg
Administration: p.o.; single dose
Result: Reached normalized serum level of 10.0 μg/mL at 1 hour.
Reached normalized serum level of 13.3 μg/mL at 2 hours.
Reached normalized serum level of 14.2 μg/mL at 4 hours.
Reached normalized serum level of 12.8 μg/mL at 6 hours.
Reached normalized serum level of 14.4 μg/mL at 8 hours.
Reached normalized serum level of 15.8 μg/mL at 12 hours.
Reached normalized serum level of 10.0 μg/mL at 18 hours.
Reached normalized serum level of 15.3 μg/mL at 24 hours.
Observed peak levels 1-2 hours post-administration.
Maintained relatively stable serum levels from 2-24 hours.
Animal Model: Two Macaca irus (male, weighing 4 kg and 5 kg, respectively)
Dosage: 200 mg/kg
Administration: p.o.; single dose
Result: Reached serum level of 10.4 μg/mL at 2 hours in monkey No. 635.
Reached serum level of 20.0 μg/mL at 4 hours in monkey No. 635.
Reached serum level of 29.2 μg/mL at 6 hours in monkey No. 635.
Reached serum level of 32.6 μg/mL at 8 hours in monkey No. 635.
Reached serum level of 33.0 μg/mL at 12 hours in monkey No. 635.
Reached serum level of 14.7 μg/mL at 24 hours in monkey No. 635.
Reached serum level of 12.7 μg/mL at 2 hours in monkey No. 636.
Reached serum level of 24.6 μg/mL at 4 hours in monkey No. 636.
Reached serum level of 32.7 μg/mL at 6 hours in monkey No. 636.
Reached serum level of 42.4 μg/mL at 8 hours in monkey No. 636.
Reached serum level of 49.4 μg/mL at 12 hours in monkey No. 636.
Reached serum level of 50.4 μg/mL at 24 hours in monkey No. 636.
Observed peak levels at 12 hours or later post-administration.
Animal Model: Sprague-Dawley (mature nulliparous, 200 to 250 g body weight, pregnancy model via mating with fertile males)
Dosage: 0.25 mg/rat; 1 mg/rat; 2.5 mg/rat; 5 mg/rat; 10 mg/rat
Administration: s.c.; daily from pro-oestrus to Day 6
Result: Completely inhibited pregnancy (0 decidual sites per rat) at subcutaneous doses of 2.5, 5.0, and 10 mg/rat daily from pro-oestrus to Day 6.
Animal Model: Mice (25-28 g body weight, pregnancy model)
Dosage: 1.0 mg/mouse; 2.5 mg/,ouse; 5.0 mg/mouse
Administration: s.c.; daily from Day 1 to Day 8
Result: Inhibited pregnancy at subcutaneous doses of 1.0, 2.5, and 5.0 mg/mouse daily from Day 1 to Day 8, with only 1/5 mice showing reduced, non-progressing decidual sites at the 1.0 and 5.0 mg/mouse doses.
Animal Model: Mice (25-28 g body weight, pregnancy model)
Dosage: 0.05 mg/mouse; 0.10 mg/mouse; 0.25 mg/mouse; 1 mg/mouse; 5.0 mg/mouse
Administration: p.o.; daily from Day 1 to Day 8
Result: Significantly inhibited pregnancy at the minimal effective oral dose of 0.25 mg/mouse daily; complete pregnancy inhibition was not achieved with any tested oral dose.
Animal Model: Sprague-Dawley (immature male, 26 to 28 days of age)
Dosage: 0.05 mg/rat; 0.8 mg/rat; 1.6 mg/rat; 3.2 mg/rat; 6.4 mg/rat
Administration: s.c.; daily for 10 days
Result: Observed no significant changes in testes, seminal vesicle, or levator ani weights, or body weight gain at 1.6 mg/rat (equivalent to minimal 100% effective anti-fertility dose) compared to controls.
Observed slight reductions in testes (1.10 g vs. 1.34 g control), seminal vesicle (12 mg vs. 17 mg control), and levator ani (25 mg vs. 33 mg control) weights, plus reduced body weight gain (42 g vs. 50 g control) at 6.4 mg/rat (four times the anti-fertility dose).
Animal Model: Sprague-Dawley (immature bilaterally ovariectomized, ~70 g body weight)
Dosage: 0.05 mg/rat; 0.20 mg/rat; 0.40 mg/rat; 1.0 mg/rat; 2.0 mg/rat
Administration: p.o.; daily for 10 days
Result: Did not increase uterine weight compared to vehicle controls (average uterine weight 25.2 mg, not significantly different from controls) at any tested oral dose.
Did not significantly reduce the uterine weight increase induced by concomitant oestradiol administration (122 mg in oestradiol-only group, no significant difference with U-11634 co-administration) at any tested dose.
Animal Model: Sprague-Dawley (immature castrated male, ~100 g body weight)
Dosage: 0.5 mg/rat; 8.0 mg/rat
Administration: p.o.; daily for 10 days
Result: Did not significantly increase seminal vesicle (control 6.0 mg) or prostate (control 32.2 mg) weights compared to vehicle controls at any tested oral dose.
Animal Model: Sprague-Dawley (pregnant females)
Dosage: 12.5 mg/kg; 25 mg/kg; 50 mg/kg
Administration: p.o.; daily from Day 9 to Day 15 of pregnancy
Result: No significant differences between treated and control groups in average number of foetuses per litter, average foetal weight, crown-rump distance, number of implantation sites, or number of resorption sites.
No foetal deaths, and only one isolated foetal abnormality (no tail) in the 50 mg/kg group.

化学信息

分子量 277.26
分子式 C11H10F3NO2S
CAS No. 3414-47-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础